djh860

LGND is at the bottom of its range earnings reoprt 2/16/22

ロング
NASDAQ:LGND   Ligand Pharmaceuticals Incorporated
they last reported sales were up 59% and profits were FAT because most of their revenues are from royalties so cost of sales is near zero.
This looks like a reasonable spot to buy in front of earnings.
www.earningswhispers....com/epsdetails/lgnd
免責事項

これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。